Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects
Sponsor: ViiV Healthcare
Listed as NCT04425902, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by ViiV Healthcare, it has been updated 10 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Feb 2024 [monthly]
Completed PHASE1
-
May 2021 — Jun 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .